Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
Results in adults with small noncleaved cell (SNCL) lymphoma treated with a short duration. Intensive chemotherapy protocol also used in pediatric patients (Meeting abstract).
Proc Annu Meet Am Soc Clin Oncol; 13:A1252 1994. Unique Identifier : AIDSLINE ICDB/94601248 Magrath IT; Adde M; Shad A; Wittes RE; Horak ID; NCI, Bethesda, MD
Abstract:
We have treated 20 adult patients with SNCL (12 BL, 7 non-BL, and 1 indeterminate) with an intensive chemotherapy protocol. None of the patients were infected with HIV. The protocol consisted of two regimens, A and B. Regimen A included CTX, ADR, VCR, and high dose MTX, and regimens B: IFOS, VP16 and high dose Ara-C. Two (alternating) cycles of each regimen were given to high risk patients (15), and 3 cycles of regimen A to low risk patients (5). Each cycle commenced as soon as granulocytes recovered to 1000 per cu mm. The total duration of therapy was 12-16 wk for high risk patients and 9-12 wk for low risk patients. All patients received IT Ara-C and MTX. 6 patients were Stage I, 11 Stage III and 3 Stage IV according to the St. Jude classification used for pediatric SNCL. The age range was 18 to 59 years (median, 25 years). Low risk patients had a single extra-abdominal mass and an LDH less than 350. All other patients were considered high risk (mean LDH 954 iu/l). 5 patients are too early to evaluate at this time (less than 6 mo from the start of therapy). All 15 evaluable patients achieved CR and remain in CR with a median follow up of 24 mo (range 6-51 mo). Most patients are already beyond the high risk period for relapse (within 10 months from the start of treatment). Toxicity was no worse in adults than in children; the durations of myelosuppression, incidence of sepsis and mucositis were similar, although adults appeared to develop neuropathy more often. The preliminary results of this study are excellent, even in very high risk patients, and suggest that adults with SNCL have a similar prognosis to children when treated with an appropriate, intensive chemotherapy regimen.
Keywords: Adolescence Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Human Lymphoma, Small Noncleaved-Cell/MORTALITY/PATHOLOGY/*THERAPY Male Middle Age Neoplasm Staging Survival Rate ABSTRACT
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
